Literature DB >> 11569535

Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?

A Barzilai1, E Melamed, A Shirvan.   

Abstract

Parkinson's disease is a progressive neurological disease caused by rather selective degeneration of the dopaminergic neurons in the substantia nigra. Though subject to intensive research, the etiology of this nigral loss is still undetermined and treatment is basically symptomatic. The current major hypothesis is that nigral neuronal death in PD is due to excessive oxidative stress generated by auto and enzymatic oxidation of the endogenous neurotransmitter dopamine (DA), the formation of neuromelanin (NM) and the presence of a high concentration of iron. In this review article although we concisely describe the effects of NM and iron on neuronal survival, we mainly focus on the molecular mechanisms of DA-induced apoptosis. DA exerts its toxic effects through its oxidative metabolites either in vitro or in vivo The oxidative metabolites then activate a very intricate web of signals, which culminate in cell death. The signal transduction pathways and genes, which are associated with DA toxicity are described in detail.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11569535     DOI: 10.1023/a:1010991020245

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  122 in total

1.  Formation of DNA adducts and oxidative base damage by copper mediated oxidation of dopamine and 6-hydroxydopamine.

Authors:  G Lévay; Q Ye; W J Bodell
Journal:  Exp Neurol       Date:  1997-08       Impact factor: 5.330

2.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

Authors:  G Walkinshaw; C M Waters
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

3.  Neuronal pigments: spectroscopic characterization of human brain melanin.

Authors:  K C Das; M B Abramson; R Katzman
Journal:  J Neurochem       Date:  1978-03       Impact factor: 5.372

Review 4.  Deficiencies of NADH and succinate dehydrogenases in degenerative diseases and myopathies.

Authors:  T P Singer; R R Ramsay; B A Ackrell
Journal:  Biochim Biophys Acta       Date:  1995-05-24

5.  Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.

Authors:  J P Spencer; P Jenner; S E Daniel; A J Lees; D C Marsden; B Halliwell
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

6.  Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice.

Authors:  A Hochman; H Sternin; S Gorodin; S Korsmeyer; I Ziv; E Melamed; D Offen
Journal:  J Neurochem       Date:  1998-08       Impact factor: 5.372

7.  Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine.

Authors:  Y Glinka; K F Tipton; M B Youdim
Journal:  Eur J Pharmacol       Date:  1998-06-12       Impact factor: 4.432

8.  Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.

Authors:  E C Hirsch; J P Brandel; P Galle; F Javoy-Agid; Y Agid
Journal:  J Neurochem       Date:  1991-02       Impact factor: 5.372

9.  Possible role of neuromelanin in the pathogenesis of Parkinson's disease.

Authors:  D M Mann; P O Yates
Journal:  Mech Ageing Dev       Date:  1983-02       Impact factor: 5.432

10.  Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease.

Authors:  J P Spencer; A Jenner; O I Aruoma; P J Evans; H Kaur; D T Dexter; P Jenner; A J Lees; D C Marsden; B Halliwell
Journal:  FEBS Lett       Date:  1994-10-24       Impact factor: 4.124

View more
  13 in total

Review 1.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  Intranigral dopamine toxicity and alpha-synuclein response in rats.

Authors:  Cristina Gómez-Santos; Pol Giménez-Xavier; Isidre Ferrer; Santiago Ambrosio
Journal:  Neurochem Res       Date:  2006-06-28       Impact factor: 3.996

3.  Oxidative stress in a model of toxic demyelination in rat brain: the effect of piracetam and vinpocetine.

Authors:  Omar M E Abdel-Salam; Yasser A Khadrawy; Neveen A Salem; Amany A Sleem
Journal:  Neurochem Res       Date:  2011-03-30       Impact factor: 3.996

4.  Compromising σ-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-κB/Bcl-2-dependent mechanism: potential relevance to Parkinson's disease.

Authors:  Tomohisa Mori; Teruo Hayashi; Tsung-Ping Su
Journal:  J Pharmacol Exp Ther       Date:  2012-03-07       Impact factor: 4.030

5.  Dopamine modifies oxygen consumption and mitochondrial membrane potential in striatal mitochondria.

Authors:  Analía Czerniczyniec; Juanita Bustamante; Silvia Lores-Arnaiz
Journal:  Mol Cell Biochem       Date:  2010-04-08       Impact factor: 3.396

Review 6.  The cell biology of alpha-synuclein: a sticky problem?

Authors:  Nelson B Cole; Diane D Murphy
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 7.  Combined and sequential effects of alcohol and methamphetamine in animal models.

Authors:  Alexandra M Stafford; Bryan K Yamamoto; Tamara J Phillips
Journal:  Neurosci Biobehav Rev       Date:  2021-09-17       Impact factor: 8.989

8.  Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

Authors:  Tomás González-Hernández; Ignacio Cruz-Muros; Domingo Afonso-Oramas; Josmar Salas-Hernandez; Javier Castro-Hernandez
Journal:  Front Neuroanat       Date:  2010-10-20       Impact factor: 3.856

Review 9.  Targets for neuroprotection in Parkinson's disease.

Authors:  Talene A Yacoubian; David G Standaert
Journal:  Biochim Biophys Acta       Date:  2008-10-01

10.  Pituitary adenylate cyclase activating polypeptide modulates catecholamine storage and exocytosis in PC12 cells.

Authors:  Yan Dong; Gang Ning; Andrew G Ewing; Michael L Heien
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.